Outlook Therapeutics Inc (OTLK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.67+2.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OTLK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -74.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OTLK — CFO transition
Dated 2026-08-27
CFO — Lawrence A. Kenyon: The CFO mutually agreed to step down with a named external successor appointed simultaneously, indicating an orderly succession rather than a sudden loss of leadership.
Why it matters: Better financial results show the company can manage costs. This may help investors feel more confident.
Supportive ifNet income improves to a profit in the next quarter.
Worry ifNet income worsens or remains negative in the next quarter.
Why it matters: A good launch of LYTENAVA could increase sales in a big market. This will show how well the company can follow its plan after getting approval.
Supportive ifManagement says initial sales are good. They also report more patients can access LYTENAVA.
Worry ifManagement says LYTENAVA is not gaining traction or has problems launching in the U.S.
Why it matters: This decision is crucial for Outlook's growth. Approval would allow the launch of LYTENAVA in the U.S. market.
Supportive ifThe FDA approved ONS-5010/LYTENAVA. It is the first eye treatment for wet AMD.
Worry ifThe FDA sent another Complete Response Letter (CRL). This delays approval.
Why it matters: Success in Europe can bring in more money and show that people accept the product.
Supportive ifThere are reports of good sales or partnerships for LYTENAVA in Europe.
Worry ifNot getting distribution deals or falling sales in Europe.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$491 on $10,000 · ±4.9% | How much price usually moves either way. |
| Bad day | $1,179 loss on $10,000 · 11.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,198 loss on $10,000 · 92.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA's decision will impact the timeline for ONS-5010's launch. A positive response could lead to a 2027 launch in Switzerland.
Supportive ifThe FDA grants approval for ONS-5010 after the appeal process.
Worry ifThe FDA issues another Complete Response Letter for ONS-5010.
Why it matters: More cash reserves are key for operations and launching the product. This shows financial health.
Supportive ifCash and cash equivalents rise sharply after the public offering of $51.1 million.
Worry ifCash reserves do not grow as expected. This may point to liquidity problems.
Why it matters: The result will impact the company's stock and how investors feel.
Worry ifThe company wins the appeal against the delisting notice.
Less concerning ifThe company is delisted from Nasdaq.
Why it matters: This approval is key for Outlook Therapeutics to launch its first FDA-approved product. It could significantly impact their market position in the wet AMD treatment space.
Supportive ifFDA grants approval for ONS-5010/LYTENAVA, allowing commercial launch in the U.S.
Worry ifFDA rejects the application or delays the approval beyond July 29, 2026.
Why it matters: How the market reacts to the approval will show how investors feel about Outlook's future.
Watch forThe stock price goes up a lot after FDA approves ONS-5010/LYTENAVA.
Also watch forStock price declines or remains flat despite FDA approval.
Why it matters: Managing capital is important for having enough cash. New capital raises can lower share value and affect how investors feel.
Worry ifThe company announces a new capital raise of over $50 million.
Less concerning ifNo new capital raises are announced. This shows the company is more financially stable.
Why it matters: Less loss means better financial health and more efficient operations.
Supportive ifNet losses for Q3 2026 are less than $20.3 million.
Worry ifNet losses for Q3 2026 exceed $20.3 million.
Why it matters: The launch will show if LYTENAVA can gain market traction. Success is key for future revenue.
Supportive ifLYTENAVA is launched in the U.S. by December 31, 2026.
Worry ifThe launch is delayed beyond December 2026.
Why it matters: This code is crucial for reimbursement and market access. It will impact the launch success.
Supportive ifThe company will send the HCPCS application by October 1, 2026.
Worry ifThe HCPCS application is not submitted by the deadline.
Why it matters: Success in Europe can show LYTENAVA's market potential. It can also help growth.
Supportive ifSales in Europe show a positive trend with growth in unit sales.
Worry ifSales in Europe continue to decline or remain flat.